Literature DB >> 16162902

Smoking habits in patients diagnosed with ANCA associated small vessel vasculitis.

M Haubitz1, A Woywodt, K de Groot, H Haller, U Goebel.   

Abstract

OBJECTIVES: To study the prevalence of smoking at onset of symptoms in patients with small vessel vasculitis associated with antineutrophil cytoplasmic antibodies (ANCA).
METHODS: A retrospective study, in 197 patients with ANCA associated vasculitis, of the history of cigarette smoking at onset of symptoms. Prevalence of smoking in patients with ANCA associated vasculitis was compared with age-specific values for the general population in Germany.
RESULTS: 27 (14%) patients were smokers at the time of first disease manifestation (p < 0.001, compared with the entire population); 54 (27%) had smoked previously with 1-110 pack-years (median 18) but had stopped > or = 2 years before onset of vasculitis; 116 (59%) patients were lifelong non-smokers. At onset of symptoms, active smokers were younger (median age 42 years) than patients with vasculitis (median 54 years, p < 0.01, Mann-Whitney U test) with a lower percentage of women (15%, p < 0.005, Fisher's exact test) than in the entire group (47%). Smokers, non-smokers, or ex-smokers did not differ in organ manifestation, mortality, and development of end stage renal disease and relapse rate.
CONCLUSIONS: The proportion of active smokers in the group of patients with ANCA associated vasculitis is significantly lower than in the entire population. Cigarette smoking may be associated with a reduced risk of ANCA associated vasculitis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16162902      PMCID: PMC1755219          DOI: 10.1136/ard.2004.033191

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  9 in total

Review 1.  The association between silica exposure and development of ANCA-associated vasculitis: systematic review and meta-analysis.

Authors:  José A Gómez-Puerta; Lydia Gedmintas; Karen H Costenbader
Journal:  Autoimmun Rev       Date:  2013-06-29       Impact factor: 9.754

2.  Cigarette smoking and risk of primary systemic vasculitis: a propensity score matching analysis.

Authors:  Alireza Khabbazi; Babak Alinejati; Mehrzad Hajialilo; Morteza Ghojazadeh; Aida Malek Mahdavi
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2019-05-01       Impact factor: 0.670

3.  Pneumo-Renal Syndrome in Anti- Neutrophil Cytoplasm Antibody (ANCA)-Associated Small-Vessel Vasculitis.

Authors:  Iuliana Andreiana; Simona Stancu; Andreea Avram; Ludmila Taran; Gabriel Mircescu
Journal:  Maedica (Buchar)       Date:  2015-06

4.  Association of Cigarette Smoking With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Authors:  Greg McDermott; Xiaoqing Fu; John H Stone; Rachel Wallwork; Yuqing Zhang; Hyon K Choi; Zachary S Wallace
Journal:  JAMA Intern Med       Date:  2020-06-01       Impact factor: 21.873

5.  Novel insights into the aetiology of granulomatosis with polyangiitis-a case-control study using the Clinical Practice Research Datalink.

Authors:  Fiona A Pearce; Peter C Lanyon; Richard A Watts; Matthew J Grainge; Abhishek Abhishek; Richard B Hubbard
Journal:  Rheumatology (Oxford)       Date:  2018-06-01       Impact factor: 7.580

Review 6.  What's new in the aetiopathogenesis of vasculitis?

Authors:  Paul A Brogan
Journal:  Pediatr Nephrol       Date:  2007-03-15       Impact factor: 3.714

7.  Cardiovascular disease and ANCA-associated vasculitis: are we missing a beat?

Authors:  Lauren Floyd; Adam D Morris; Alexander Woywodt; Ajay Dhaygude
Journal:  Clin Kidney J       Date:  2022-01-13

Review 8.  Environmental factors influencing the risk of ANCA-associated vasculitis.

Authors:  Wen-Man Zhao; Zhi-Juan Wang; Rui Shi; Yu-Yu Zhu; Sen Zhang; Rui-Feng Wang; De-Guang Wang
Journal:  Front Immunol       Date:  2022-09-02       Impact factor: 8.786

9.  Serum PR3-ANCA Is a Predictor of Primary Nonresponse to Anti-TNF-α Agents in Patients with Ulcerative Colitis.

Authors:  Atsushi Yoshida; Katsuyoshi Matsuoka; Fumiaki Ueno; Toshio Morizane; Yutaka Endo; Toshifumi Hibi
Journal:  Inflamm Intest Dis       Date:  2021-04-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.